US: IDE (investigational device exemption) does not necessarily equal national coverage
This article was originally published in Clinica
An FDA investigational device exemption for a product does not automatically guarantee nationwide coverage for the product, a local Medicare carrier warned last week. Saty Satya-Murti, Medicare medical director for Blue Cross and Blue shield of Kansas, says there are times when local carriers choose not to cover such investigational products.
You may also be interested in...
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
No device-related warning letters were released by the US FDA the week of 31 March.